<DOC>
	<DOCNO>NCT02055781</DOCNO>
	<brief_summary>The primary hypothesis study treatment either once-daily twice-daily pacritinib result great proportion patient thrombocytopenia myelofibrosis achieve ≥ 35 % reduction spleen volume baseline Week 24 treatment Best Available Therapy , great proportion patient achieve ≥ 50 % reduction total symptom score baseline Week 24 measure Myeloproliferative Neoplasm Symptom Assessment Form 2.0 .</brief_summary>
	<brief_title>Oral Pacritinib Versus Best Available Therapy Treat Myelofibrosis With Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Intermediate 1 2 highrisk Myelofibrosis ( per Passamonti et al 2010 ) Thrombocytopenia ( platelet count ≤ 100,000/µL ) time sign informed consent Palpable splenomegaly ≥ 5 cm physical examination Total Symptom Score ≥ 13 MPNSAF TSS 2.0 , include inactivity question Patients platelet red blood cell transfusiondependent eligible Adequate white blood cell count ( low blast count ) , liver function , renal function At least 6 month prior splenic irradiation At least 14 week since prior myelofibrosis therapy , include erythropoietic thrombopoietic agent Not pregnant , lactating , agree use effective birth control Able willing undergo frequent MRI CT assessments complete symptom assessment use patientreported outcome instrument Prior treatment 2 JAK2 inhibitor pacritinib There maximum cumulative prior JAK2 inhibitor treatment History ( plan undergo ) spleen removal surgery allogeneic stem cell transplant Ongoing gastrointestinal medical condition Crohn 's disease , Inflammatory bowel disease , chronic diarrhea , constipation Active bleeding require hospitalization screen period Cardiovascular disease , include recent history currently clinically symptomatic uncontrolled : congestive heart failure , arrhythmia , angina , QTc prolongation QTc risk factor , myocardial infarction Other malignancy within last 3 year certain limited skin , cervical , prostate , breast , bladder cancer Other ongoing , uncontrolled illness ( include HIV infection active hepatitis A , B , C ) , psychiatric disorder , social situation would prevent good care study Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post-Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Polycythemia</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Thrombocythemia , Essential</keyword>
	<keyword>Thrombocythemia</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Disease</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Splenomegaly</keyword>
	<keyword>Pacritinib</keyword>
	<keyword>MPN-SAF</keyword>
	<keyword>MPN-SAF TSS</keyword>
	<keyword>Anemia</keyword>
	<keyword>Myeloproliferative</keyword>
	<keyword>Myeloproliferative Neoplasm</keyword>
	<keyword>Spleen</keyword>
	<keyword>Spleen volume</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>SB1518</keyword>
</DOC>